ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1033

Novel Ligand-Independent Peptide Inhibitors of Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1) and T Cell Receptor (TCR): Efficacy in a Collagen-Induced Arthritis Model Suggests New Targeted Treatment for Rheumatoid Arthritis

Zu T. Shen and Alexander B. Sigalov, SignaBlok, Inc., Shrewsbury, MA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: autoimmune diseases, macrophages, rheumatoid arthritis (RA) and signal transduction, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Rheumatoid Arthritis - Animal Models I

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Macrophages and T cells are central to the pathophysiology of autoimmune diseases. Synovial macrophages, synovial fibroblasts and infiltrating T lymphocytes are the most abundant cell populations found in the synovium of patients diagnosed with rheumatoid arthritis (RA). Activation of these cells leads to the production of proinflammatory cytokines and mediators. Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1) and T cell receptor (TCR), expressed on macrophages and T cells, respectively, play a critical role in the signal transduction pathways leading to the onset and development of RA. In this study, novel ligand-independent peptide inhibitors of TREM-1 and TCR were rationally designed by employing a new model of immune signaling, the Signaling Chain HOmoOLigomerization (SCHOOL) model, and these inhibitors, for the first time, were evaluated in a mouse collagen-induced arthritis (CIA) model.

Methods: CIA was induced by immunizing male DBA/1J mice on days 0 and 21 by bovine type II collagen in Freund’s complete adjuvant. On day 24, animals were weighed, randomized across study groups and given daily intraperitoneal (IP) doses of SCHOOL TREM-1 inhibitory peptide GF-9 or TCR inhibitory peptide MG-11 in free and targeted nanoparticle-bound forms, at doses of 25 mg/kg and 2.5 mg/kg, respectively. The mice were weighed every second day and all paws were scored daily for clinical signs of arthritis.

Results: Mice treated with GF-9 or MG-11 showed a significant delay in arthritis onset as well as a striking reduction in disease severity. This effect is specific as administration of the control peptide did not affect disease onset or severity. Targeted delivery of SCHOOL peptides utilizing self-assembling lipid-peptide nanoparticles significantly increased peptide dosage efficacy.

Conclusion: This study provides clear data demonstrating that inhibition of TREM-1 and TCR signal transduction pathways using short synthetic peptides that employ a novel ligand-independent mechanism of action (SCHOOL peptides) may represent a new, targeted, and non-toxic treatment for RA. Importantly, this ligand-independent mode of TREM-1 inhibition may significantly decrease the risk of failure in clinical development because of the unknown nature of the TREM-1 ligand(s).


Disclosure: Z. T. Shen, None; A. B. Sigalov, None.

To cite this abstract in AMA style:

Shen ZT, Sigalov AB. Novel Ligand-Independent Peptide Inhibitors of Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1) and T Cell Receptor (TCR): Efficacy in a Collagen-Induced Arthritis Model Suggests New Targeted Treatment for Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/novel-ligand-independent-peptide-inhibitors-of-triggering-receptor-expressed-on-myeloid-cells-1-trem-1-and-t-cell-receptor-tcr-efficacy-in-a-collagen-induced-arthritis-model-suggests-new-targeted/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/novel-ligand-independent-peptide-inhibitors-of-triggering-receptor-expressed-on-myeloid-cells-1-trem-1-and-t-cell-receptor-tcr-efficacy-in-a-collagen-induced-arthritis-model-suggests-new-targeted/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology